Wells Fargo upgrades Zimmer Biomet Holdings to Overweight from Equal-Weight, raises price target to $123

Wells Fargo upgraded Zimmer Biomet Holdings to Overweight, raising its price target to $123 from $113, suggesting 21.3% upside from the Nov 16 close of $101.41. Recent analyst price targets range from $101 to $140.

Original reporting
Published Nov 17, 2026, 12:45 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 17, 2026, 12:56 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Wells Fargo upgrades Zimmer Biomet Holdings to Overweight from Equal-Weight, raises price target to $123 — source image
Decision brief

The 30-second read

$ZBHBullishMed
01

Why it matters

For traders, the actionable element is the rating upgrade plus the target increase, which can influence short-term positioning and options sentiment even without new company fundamentals.

02

Market read

A sell-side upgrade with a higher target can drive incremental demand for the stock, especially if it shifts consensus expectations.

03

What to watch

The article does not state the upgrade thesis or any new Zimmer Biomet operational data, so traders may discount the move versus upcoming earnings or guidance.

Relevance 7/10Novelty 5/10Timing: today, as the upgrade and raised target are newly issued

Background

The piece reports a Wells Fargo analyst action on Zimmer Biomet, including a rating change and a revised price target.

Company-level read

Ticker impact

$ZBHBullishMedium confidence
Context

Wells Fargo upgraded Zimmer Biomet to Overweight and raised its price target to $123 from $113, implying upside versus the Nov 16 close.

Expected impact

Likely modest upward bias as traders price in the analyst target increase and improved rating.

Evidence & confidence

The article is a single-bank rating change with explicit target math, but it does not provide new company fundamentals beyond the analyst action.

Market effects

Could modestly support sentiment for large-cap medical device peers via read-across to orthopedic demand expectations, though no peer-specific news is provided.

Limited, since the catalyst is company-specific analyst coverage rather than a broad regional driver.

Low, as the update is a US sell-side rating change with no global regulatory or macro linkage described.

Counterpoint

An analyst upgrade may not translate into sustained price follow-through if broader fundamentals or valuation concerns remain unchanged.

Key entities

  • Zimmer Biomet Holdings

    Subject of the analyst upgrade and price-target increase reported in the article.

  • Wells Fargo

    Brokerage issuing the Overweight upgrade and raising the price target.

Related articles

$ZBHMed

What Zimmer Biomet (ZBH) Said on Its Q3 Earnings Call

Zimmer Biomet (ZBH) reported Q3 sales growth of 13% in technology, bone cement, and surgical sales, but a 2.6% decline in global knee sales. CEO Tornos attributed knee underperformance to commercial execution. The company expects to launch its Monogram robotic system in early 2027. Q3 adjusted earnings were $1.90 per share, with margins declining but cash flow rising. Full-year sales growth guidance was raised to 4.4%-4.9%.

$ZBHMed

Truist raises Zimmer Biomet stock price target on robotics progress

Truist Securities raised Zimmer Biomet's (ZBH) price target to $114 from $106, citing 3.7% Q3 organic revenue growth, though EPS missed estimates. The stock is up 13% in a week. Analysts note progress in robotics and hip segments, but caution on knee division weakness and future risks. Other analysts also raised targets, with Stifel at $125 and Jefferies at $120.

$ZBHMed

Zimmer Biomet Holdings Inc (ZBH) (Q3 2026) Earnings Call Highlights: Guidance Raised as Hips

Zimmer Biomet (ZBH) reported Q3 2026 earnings, raising guidance despite a 2.6% decline in knee business due to sales force transition and competitive pressure. Adjusted operating margin fell 140 basis points to 25.1%, and gross margin decreased 90 basis points to 71.7%. CEO Ivan Tornos highlighted sustainable growth in hips and S.E.T. areas, but acknowledged underperformance in knees. China headwinds and sales force disruption pose risks.

$ZBHMedAI 8/10

Zimmer Biomet (ZBH) Q3 2026 Earnings Call Transcript

Zimmer Biomet (ZBH) reported Q3 2026 net sales of $2.63B, up 3.7% in constant currency. Growth was driven by hips, S.E.T., and technology, while knees declined 2.6%. The company raised its 2026 guidance, expecting 3% to 3.5% constant currency sales growth and $8.50 to $8.60 adjusted EPS. Strategic priorities include sales force transition, robotics expansion, and diversification.